Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window Joint outcome table analysis of the ECASS 3 trial

Jeffrey L. Saver, Jeffrey Gornbein, James Grotta, David Liebeskind, Helmi Lutsep, Lee Schwamm, Phillip Scott, Sidney Starkman

Research output: Contribution to journalArticlepeer-review

91 Scopus citations

Fingerprint

Dive into the research topics of 'Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window Joint outcome table analysis of the ECASS 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences